Medivir's new cold sore cream has passed clinical phase I with good results

Medivir's new cold sore cream has passed clinical phase I with good results Medivir is in alliance with AstraZeneca developing a new patent-pending treatment of cold sores and genital herpes. The phase I clinical study is now concluded with results showing a good safety profile. Appointment of leading international research centres for the clinical phase II trial is well underway. Cold sores are primarily caused by herpes simplex virus type 1, HSV-1, and genital herpes is primarily caused by HSV-2. The sores lead to swelling, rashes, blistering and varying degrees of pain. Each year, 250-400 million episodes of cold sores occur, as do approximately 100 million episodes of genital herpes in Western Europe, the US and Japan. Approximately 80 per cent of the adult population is estimated to be chronically infected with HSV-1, and 20 per cent with HSV-2. Total global sales of drugs against herpesviruses in 1998 amounted to approximately 750 MGBP. Around half of the total sales related to HSV infections. Huddinge June 29th 1999 Medivir AB (publ) For more information please contact: Anna Bernsten, Vice President Business Development and Investor Relations, Medivir AB, phone no 08-608 31 05, 0709-369 069 or e-mail: A clinical phase I study is a study with healthy volunteers primarily focused on proving that a particular substance is safe for use in humans. A clinical phase II study is a study with patients suffering from the disease to be treated. The primary objective is to show that the substance has the intended medical effect. Medivir is a research and development company which develops new and better substances for the treatment of infectious diseases. The subsidiary company CCS AB develops, manufactures and markets body-care products and pharmaceuticals. The Group consists of the parent company, Medivir AB, the CCS AB subsidiary and UK company CCS (UK) Ltd. ------------------------------------------------------------ Please visit for further information The following files are available for download:

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.